Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 63Myelodysplastic Syndromes 27Leukemia 13Leukemia, Myelomonocytic, Chronic 12Congenital Abnormalities 9Recurrence 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myeloproliferative Disorders 8Primary Myelofibrosis 6Thrombocythemia, Essential 4Polycythemia Vera 4Neoplasms 4Melanoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Blast Crisis 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2Neuroblastoma 2Neoplasm Metastasis 2Myelodysplastic-Myeloproliferative Diseases 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2

Interventions

venetoclax 6Azacitidine 6Cytarabine 5fludarabine 4Methotrexate 3fludarabine phosphate 2aldesleukin 2RO6839921 2Mitoxantrone 2Interleukin-2 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Decitabine 2Dasatinib 2zileuton 1thymoglobulin 1spartalizumab 1sabatolimab 1quizartinib 1pulrodemstat besilate 1posaconazole 1plerixafor 1gilteritinib 1etoposide phosphate 1emvododstat 1daratumumab 1blinatumomab 1Sorafenib 1Sirolimus 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myeloid × Decitabine × Clear all
NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Novartis

Phase 1 Completed
241 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02203773 2023-05-16

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

AbbVie

Phase 1 Terminated
212 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡